Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: AIN457

First Posted Date: 2011-09-13

Last Posted Date: 2016-03-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT01433250

Locations: 🇺🇦
Novartis Investigative Site, Vinnitsya, Ukraine

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

Phase 2

Completed

Conditions: Cachexia

Interventions: Drug: BYM338 active drug
Drug: Placebo

First Posted Date: 2011-09-13

Last Posted Date: 2016-03-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT01433263

Locations: 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom

Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

Phase 2

Terminated

Conditions: Fragile X Syndrome

Interventions: Drug: AFQ056

First Posted Date: 2011-09-13

Last Posted Date: 2016-03-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 119

Registration Number: NCT01433354

Locations: 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Phase 3

Completed

Conditions: Acute Gouty Arthritis

Interventions: Drug: Canakinumab 150mg in prefilled syringe

First Posted Date: 2011-09-09

Last Posted Date: 2021-07-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 397

Registration Number: NCT01431638

Locations: 🇱🇹
Novartis Investigative Site, Vilnius, Lithuania

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Phase 1

Completed

Conditions: Uveal Melanoma

Interventions: Drug: AEB071

First Posted Date: 2011-09-08

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 153

Registration Number: NCT01430416

Locations: 🇺🇸
Memorial Sloan Kettering MSKCC 4, New York, New York, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸
Dana Farber Cancer Institute DFCI - Brookline, Boston, Massachusetts, United States

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Midostaurin

First Posted Date: 2011-09-07

Last Posted Date: 2021-05-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT01429337

Locations: 🇷🇴
Novartis Investigative Site, Cluj, Napoca, Romania
🇺🇸
American Research Corporation Inc, San Antonio, Texas, United States

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Phase 1

Completed

Conditions: Healthy Volunteers
Atopic Dermatitis
Netherton Syndrome

Interventions: Drug: BPR277 ointment
Drug: Placebo (Vehicle)
Drug: BPR277 ointment (controlled application)
Drug: BPR277

First Posted Date: 2011-09-02

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT01428297

Locations: 🇳🇱
Novartis Investigative Site, Utrecht, The Netherlands, Netherlands

Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: vildagliptin

First Posted Date: 2011-08-31

Last Posted Date: 2017-02-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT01426802

Locations: 🇪🇬
Investigative site, Cairo, Egypt

A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Secukinumab

First Posted Date: 2011-08-31

Last Posted Date: 2015-08-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT01426789

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase 2

Completed

Conditions: Sporadic Inclusion Body Myositis

Interventions: Biological: BYM338
Biological: Placebo

First Posted Date: 2011-08-25

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT01423110

Locations: 🇺🇸
Novartis Investigative Site, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy